Fibrinolytic drugs have been used with varying degrees of enthusiasm for treating various thrombotic disorders including deep venous thrombosis and pulmonary embolism.1,2 Recently, the use of fibrinolysis in acute myocardial infarction has come to the fore. Streptokinase and two new fibrinolytic drugs (Anisoylated Plasminogen Streptokinase Activator Complex - APSAC, and Recombinant Tissue Plasminogen Activator - rTPA) have been investigated and shown to achieve reperfusion of thrombosed coronary arteries, so reducing myocardial necrosis. Only streptokinase and APSAC have been shown to decrease mortality, and then only if they are given soon after the onset of symptoms.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.